NRX TARGETS 2026 KETAFREE APPROVAL AND OUTLINES SPARC-TMS TRIAL IN 400 PATIENTS BACKED BY MILITARY FUNDING - SEEKINGALPHA

2026 approval catalyst and 400-patient trial with military funding.